BeOne’s TEVIMBRA Gets CHMP Nod for NSCLC Treatment
Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological response If...
